;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Novo Nordisk's obesity drug Wegovy debuts in Thailand

Published by Global Banking and Finance Review

Posted on April 28, 2025

Featured image for article about Headlines

By Panu Wongcha-um

BANGKOK (Reuters) -Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary said on Monday, marking the injectable drug's first entry into the Southeast Asian market.

First launched in 2021, Wegovy helped make Novo Nordisk Europe's most valuable listed company until recently, worth $615 billion at its peak.

Wegovy is available in more than a dozen countries including the United States, Japan and China, with Thailand becoming its latest market.

"We actually received the Thai FDA approval already in 2023," said Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary. He noted that Novo was making Wegovy available in Thailand ahead of rival Eli Lilly's Zepbound weight loss drug.

Bruland declined to provide details on Wegovy's pricing in Thailand, which has a population of around 66 million, or Novo Nordisk's plans for expansion into other Southeast Asian markets.

Wegovy is currently available for prescription in private hospitals around the country and will be available soon in public hospitals, Bruland said.

"Over the last four years, we have invested approximately 500 million Thai baht in clinical trials in Thailand," he said.

Novo Nordisk's diabetes drug Ozempic, which contains the same active ingredient as Wegovy, is already available in Thailand.

About 42% of Thailand's adult population is considered obese, and the rate of obesity in school children surged from 5.8% to 15% within two decades, according to data from the country's health ministry.

"If we then look at the economic impact that this has, approximately 1 percent of GDP is used for health-related costs that come with obesity and productivity loss," Bruland said.

"We believe with this innovation, we can make a big difference and hopefully bend this curve."

(Reporting by Panu Wongcha-um; Editing by Emelia Sithole-Matarise)